ArticleClinical ophthalmology (Auckland, N.Z.)2025
Discordance Among Patients and Ophthalmologists Regarding the Burden of Intravitreal Injections.
Article in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Article
- Aflibercept 8 mg for diabetic macular edema and neovascular age-related macular degeneration: an italian expert consensus paper.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Faricimab in Treatment-Naïve nAMD: Regional UK Real-World Experience.Advances in therapy · 2026Article
- Continuing Medical Education as a Tool to Accelerate the Adoption of Extended-Duration Intravitreal Anti-VEGFs.Journal of CME · 2026Article
- Psychosocial determinants of anti-VEGF treatment adherence in AMD patients: optimization of one-stop intravitreal injection service model.Frontiers in medicine · 2026Article
- Anti-VEGF Therapies in Retinal Disorders: Current Landscape and Future Directions.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- One-year clinical outcomes of four-dose induction versus immediate treat-and-extend faricimab regimens in pretreated neovascular age-related macular degeneration.BMC ophthalmology · 2025Article
- Discordance Among Patients and Ophthalmologists Regarding the Burden of Intravitreal Injections.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To determine how patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) perceive their disease and its treatment and to assess the degree of alignment between patient and clinician perceptions. Patients and Methods: In June 2024 a survey of 101 patients (50 with DME and 51 with nAMD) and 100 ophthalmologists who treat these conditions completed surveys. Results: Sixty-six percent and 86% of patients with DME and nAMD, respectively, reported receiving intravitreal injections at least once every 8 weeks. Eighty-two percent required a caregiver and/or public transportation to get to their appointments. The most significant symptoms for patients with DME were vision loss over time (2.89 out of 4.0) and blurred or double vision (2.76), and for those with nAMD were poor night vision (3.43), seeing in low-light conditions (3.27), and blurred vision (2.96). The proportion of patients who were dissatisfied with the education and counseling they received about their disease was greater for nAMD (31%) compared with DME (11%; Conclusion: This study highlights the significant burden experienced by patients undergoing intravitreal injections and identifies key areas of discordance between patient and clinician perceptions. Targeted education and counseling focused on these differences is indicated to improve patient satisfaction and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.